Results 111 to 120 of about 5,245,251 (341)

Effect of prior antiplatelet therapy on major adverse cardiac events in patients diagnosed with infective endocarditis: Population-based retrospective cohort study

open access: yesJournal of Medical Sciences, 2019
Background: Infective endocarditis (IE) occurs with an incidence of about 3–10 per 100,000 person-years globally. Those with infective endocarditis complicated embolic events have worse outcomes.
Tsung-Ta Chiang   +11 more
doaj   +1 more source

Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence

open access: yesPharmacogenomics and Personalized Medicine, 2020
In patients undergoing percutaneous coronary intervention (PCI), the standard of care is dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin.
Megan N. Gower   +5 more
semanticscholar   +1 more source

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Primary autoimmune thrombocytopenia (ITP) is characterized by thrombocytopenia, bleeding, and reduced health‐related quality of life. In the Phase 3 ADVANCE IV study, intravenous efgartigimod induced significant platelet count responses versus placebo in patients with chronic ITP. ADVANCE SC, a Phase 3, multicenter, randomized, double‐blinded,
Nichola Cooper   +546 more
wiley   +1 more source

Racial and ethnic differences in restarting antiplatelet therapy in patients with primary intracranial hemorrhage: a systematic review and meta-analysis

open access: yesBMC Neurology
Background There has long been clinical disagreement over the resumption of antiplatelet therapy in patients with primary intracranial hemorrhage (ICH).
Xuechang Wang   +3 more
doaj   +1 more source

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms [PDF]

open access: yes, 2018
We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs.
Arellano-Rodrigo, Eduardo   +41 more
core   +5 more sources

Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection: The Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results.

open access: yesJAMA Neurology, 2019
Importance Extracranial carotid and vertebral artery dissection is an important cause of stroke, particularly in younger individuals. In some but not all observational studies, it has been associated with a high risk of recurrent stroke.
H. Markus   +4 more
semanticscholar   +1 more source

Dupilumab Beyond the Airway: Decreased Morbidity in a Real‐World Analysis

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Post hoc analyses of clinical trials have characterized dupilumab's adverse effects, yet the real‐world impact in chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma is not well described. This study aims to characterize the risks of lymphoma, cardiovascular events, eosinophilia, joint pain, inflammatory arthritis, and ...
Emma J. Anisman   +9 more
wiley   +1 more source

Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation [PDF]

open access: yes, 2016
This is an Accepted Manuscript of an article published by Taylor & Francis GroupNon-vitamin K antagonist oral anticoagulants (NOACs) reduce the risk of thromboembolism in patients with atrial fibrillation (AF).
Artman, Benjamin   +8 more
core   +2 more sources

Cerebrospinal Fluid Amyloid‐β Biomarkers Predict Future Hemorrhage in Patients with Cerebral Amyloid Angiopathy

open access: yesAnnals of Neurology, EarlyView.
Objective Accurately predicting future hemorrhagic events in patients with cerebral amyloid angiopathy (CAA) remains a major clinical challenge. It is unknown whether cerebrospinal fluid (CSF) biomarkers of amyloid‐beta (Aβ) pathology are associated with increased hemorrhage risk in this population.
Philipp Arndt   +15 more
wiley   +1 more source

Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably! [PDF]

open access: yes, 2017
No abstract ...
Aspirin Myocardial Infarction Study Research Group   +23 more
core   +1 more source

Home - About - Disclaimer - Privacy